Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated the safety and tolerability of anifrolumab, a monoclonal antibody targeting the type I interferon (IFN) receptor, in Japanese patients with moderate-to-severe systemic lupus erythematosus (SLE).
|
30793642 |
2020 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the current study provides a direct link between type I IFN pathway overactivation and the abnormally high frequency and proinflammatory properties of transitional B cells in active SLE patients, which contributes to the understanding of the roles of type I IFNs and B cells in the pathogenesis of SLE.
|
29563616 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that diseases associated with anti-SSA/Ro autoantibodies, such as systemic lupus erythematosus and Sjögren syndrome, are linked with an upregulation of IFN and type I IFN-stimulated genes, including sialic acid-binding Ig-like lectin 1 (Siglec-1), a receptor on monocytes/macrophages, recent attention has focused on a potential role for IFN and IFN-stimulated genes in the pathogenesis of congenital heart block (CHB).
|
30518570 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous reports have described the appearance of systemic lupus erythematosus (SLE) cases following interferon-α (IFN-α) therapy, IFN-regulated gene expression is significantly increased in SLE, and an association between SLE and gene variants belonging to IFN downstream pathways has been shown.
|
31190735 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High type I IFN activity correlated with levels of IFN-γ and IFN-α and associated with active SLE in most domains: weight loss, fatigue, fever, rash, lymphadenopathy, arthritis, nephritis and haematological manifestations.
|
31036046 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, these results suggest that closing the door on targeting the type 1 IFN pathway in SLE may be premature and highlight the emerging question of whether an organ-specific approach toward lupus trials and treatment should be the wave of the future.
|
30776023 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lupus and control CD8+ T cells significantly increased STAT1 mRNA levels after treatment with IFNα.
|
30674474 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations: ALB: albumin; ARHGDIB: Rho GDP dissociation inhibitor beta; APOL1: apolipoprotein L1; ATG5: autophagy related 5; ATG7: autophagy related 7; ATG16L2: autophagy related 16 like 2; BECN1: beclin 1; CDKN1B: cyclin dependent kinase inhibitor 1B; CLEC16A, C-type lectin domain containing 16A; CYBB: cytochrome b-245 beta chain; DC: dendritic cell; DRAM1: DNA damage regulated autophagy modulator 1; eQTL: expression quantitative trait loci; GWAS: genome-wide association study; IFNA: interferon alpha; IRGM: immunity related GTPase M; LRRK2: leucine rich repeat kinase 2; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MTMR3: myotubularin related protein 3; LAP" LC3-associated phagocytosis; LN: lupus nephritis; NOD: non-obese diabetic; NPHS2: NPHS2, podocin; PBMC: peripheral blood mononuclear cell; RUBCN: rubicon autophagy regulator; SLE: systemic lupus erythematosus.
|
30755075 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensing self-nucleic acids through toll-like receptors in plasmacytoid dendritic cells (pDCs), and the dysregulated type I IFN production, represent pathogenic events in the development of the autoimmune responses in systemic lupus erythematosus (SLE).
|
31299881 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, sole upregulation of IFN-α is sufficient to induce SLE, and the double-negative T cells expanded by IFN-α are directly responsible for the organ manifestations, such as lupus skin disease or nephritis.
|
31324723 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus.
|
31724446 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate how IFN responses in SLE keratinocytes contribute to development of CLE.
|
30745462 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutrophil extracellular traps (NETs) are considered a potential source of antigenic trigger in SLE that can lead to type I IFN gene induction, as well as increased autoantibody production.
|
31130331 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed at exploring the role of one such gene, α/β-hydrolase domain-containing 6 (ABHD6), in regulation of IFN-α induction in SLE patients.
|
30728209 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show a novel role for BCAP in promoting TLR-induced IFN-α production in pDC and in systemic lupus erythematosus pathogenesis.
|
30936294 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunologically, anti-CD40 treatment disrupted multiple processes that contribute to the pathogenesis of systemic lupus erythematosus (SLE), including autoreactive B cell activation, T effector cell function in target tissues, and type I IFN production.
|
31109957 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BIIB059 administration in patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune infiltrates in skin lesions, and decreased CLASI-A score.
|
30645203 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that conventional dendritic cells (cDCs) from predisease lupus-prone B6.NZM Sle1/Sle2/Sle3 triple congenic (TCSle) mice produce more IL-10 than wild-type congenic cDCs upon TLR stimulation, and this overproduction is prevented by blocking the type I IFN receptor (IFNAR) with specific Abs.
|
31216373 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
10-week old female lupus-prone (NZM2328), wild-type (BALB/c) and iNZM mice (lack a functional type I IFN receptor on NZM2328 background) were treated on their dorsal skin with 100 mJ/cm<sup>2</sup> of UVB for 5 consecutive days.
|
31248690 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-γ<sup>+</sup> cells in the CD4<sup>+</sup>CD25<sup>+</sup>T subset fresh-isolated from SLE patients increased slightly, but IFN-γ-producing response to stimulation in CD4<sup>+</sup>CD25<sup>+</sup>T subset of SLE decreased.
|
31019943 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of IFNα and the four ISGs were all significantly higher in SLE patients than in healthy controls ( p < 0.05).
|
29338588 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathogenesis of ASIA-MO is not clear, but is characterized by chronic granulomatous inflammation, like the pristane model in mice, with increase of proinflammatory cytokines: type I interferons (IFNα and IFNß), systemic lupus erythematosus (SLE), and erosive arthritis.
|
29619588 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant advances in the understanding of the molecular basis of innate immunity have led to the identification of interferons (IFNs), particularly IFN-α, as central mediators in the pathogenesis of Systemic Lupus Erythematosus.
|
29108825 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase II studies in SLE suggest beneficial effects of blocking the type I IFN receptor.
|
29889694 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IFN-α gene expression was measured by real-time polymerase chain reaction (PCR) assay in 123 Egyptian female patients with SLE and in 100 females as a healthy control group.
|
28659049 |
2018 |